Leaflet BERINERT 3000 3000UI powder+solvent for injection


Indicated for: hereditary angioedema

Route of administration: injectable

Substance: human C1 esterase inhibitor (C1 esterase inhibitor)

ATC: B06AC01 (Blood and blood forming organs | Other hematological agents | Drugs used in hereditary angioedema)

Human C1 esterase inhibitor is used for the treatment of hereditary angioedema, a genetic condition characterized by recurrent episodes of severe swelling. It works by regulating the activity of the complement system and preventing its excessive activation.

The medication is administered intravenously, as directed by a doctor. It is important to monitor the patient for adverse reactions during the infusion.

Side effects may include headache, nausea, dizziness, or injection site reactions. In rare cases, severe allergic reactions may occur.

This medication is not recommended for patients with hypersensitivity to human plasma proteins or severe IgA deficiency.

General data about BERINERT 3000 3000UI

  • Substance: human C1 esterase inhibitor
  • Date of last drug list: 01-06-2019
  • Commercial code: W65559001
  • Concentration: 3000UI
  • Pharmaceutical form: powder+solvent for injection
  • Quantity: 1
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: CSL BEHRING GMBH - GERMANIA
  • Holder: CSL BEHRING GMBH - GERMANIA
  • Number: 13299/2020/01
  • Shelf life: 36 months

Pharmaceutical forms available for human C1 esterase inhibitor

Concentrations available for human C1 esterase inhibitor

  • 1500UI
  • 2000UI
  • 3000UI
  • 500 U
  • 500UI